During the avian flu pandemic in 2005, the company set up a facility used exclusively to manufacture respiratory protection masks. In this particular market, the French government selected Macopharma as one of its five official suppliers.
In 2007, the customer portfolio was diversified to serve industrial users, B-to-B customers and healthcare providers. Macopharma currently sells FFP2 respiratory protective devices that comply with class of filtration efficiency requirements under standard EN 149:2009.
During the 2009 H1N1 flu pandemic, the facility’s workforce was ramped up to 175 employees to be able to respond to the French government’s additional needs.